

## Our Business <sup>[1]</sup>

Novartis focuses its business on two divisions with innovation power and global scale: pharmaceuticals and generics. The two divisions are supported by our research organisation, the [Novartis Institutes for BioMedical Research \(NIBR\)](#) <sup>[2]</sup>, and a centralised services group, Novartis Business Services, to facilitate collaboration across our divisions, and drive efficiency and productivity gains.

We aim to develop innovative products in growing areas of healthcare. At the same time, we are expanding our presence in the emerging markets of Asia, Africa and Latin America, where there is fast-growing demand for access to high-quality medicines and healthcare.



## Pharmaceuticals

Pharmaceuticals develops innovative, patent-protected medicines to enhance health outcomes for patients and health-care providers. The division is at the forefront of development and commercialization in oncology, primary care and specialty medicines.

[Read More](#) <sup>[3]</sup>



## Sandoz (Generics)

Sandoz is a global leader in the rapidly growing generics industry. Its products – which are focused in Retail Generics, Biopharmaceuticals & Oncology Injectables, and Anti-Infectives – help make affordable, high-quality medicines available to more people.

[Read More](#) <sup>[4]</sup>

**Accordion Type:**

Collapsible

---

**Source URL:** <https://www.novartis.com.au/about-us/our-business>

**Links**

[1] <https://www.novartis.com.au/about-us/our-business>

[2] <http://www.nibr.com/>

[3] <http://www.novartispharmaceuticals.com/en>

[4] <http://www.sandoz.com/>